11
4
Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
TP1053L |
Protein Kinase C 19-31 acetate
Protein Kinase C 19-31 acetate(121545-65-1 free base),PKC (19-31) acetate |
PKC | Chromatin/Epigenetic; Cytoskeletal Signaling |
Protein Kinase C 19-31 acetate(121545-65-1 free base) 是一种蛋白激酶 C (PKC) 的肽抑制剂,源自 PKCa 的假底物调节结构域(残基 19-31),在 25 位用丝氨酸取代野生型丙氨酸作为蛋白激酶 C 底物肽,用于测试蛋白激酶 C 活性。 | |||
T76419 |
Protein Kinase C γ Peptide
|
||
Protein Kinase C γ Peptide,Protein Kinase Cγ 的肽片段,为显性共济失调的致病蛋白,能够负向调节隐性共济失调相关失联蛋白的核输入。 | |||
T76421 |
Protein Kinase C β Peptide
|
||
Protein Kinase C β Peptide为Protein Kinase Cβ的多肽片段,与高血糖降低内皮源性一氧化氮(NO)生成相关。抑制Protein Kinase Cβ能够减轻急性高血糖导致的内皮依赖性血管舒张功能障碍。 | |||
T76387 |
Protein kinase C substrate
|
||
Protein kinase C substrate,蛋白激酶C的底物,关键用于蛋白质检测。作为信号转导中重要的调控元素,Protein kinase C通过特定底物的磷酸化作用发挥其功能。 | |||
T76388 |
Protein kinase C α peptide TFA
|
||
Protein kinase C α peptide (TFA) 为PKC-α的脂质依赖性丝氨酸/苏氨酸蛋白激酶多肽片段,关键调节细胞生存、增殖、分化、迁移及粘附等过程。 | |||
T76444 |
Protein Kinase C (660-673)
|
||
Protein Kinase C (660-673) (PKC βII (660-673)) 是具有 RACK1结合亲和力的 PKCβII V5 肽。 | |||
T76422 |
Protein Kinase C (661-671)
|
||
Protein Kinase C (661-671) 是蛋白激酶 C (PKC) β1 亚种的片段肽。PKC 在细胞生长控制和肿瘤促进中发挥作用。 | |||
T76008 |
Protein Kinase C (19-31) (TFA)
|
||
Protein Kinase C (19-31) TFA 是蛋白激酶 C (PKC)的抑制剂,是由 PKCa (残基 19-31) 伪底物调控域衍生而来,25 位丝氨酸取代野生型丙氨酸作为蛋白激酶 C 底物肽,用于检测蛋白激酶 C 的活性。Protein kinase C (PKC) TFA 通过磷酸化丝氨酸和苏氨酸氨基酸残基上的羟基来调控其它蛋白的功能。 | |||
T76456 |
Protein Kinase C (19-35) Peptide
|
||
Protein Kinase C (19-35) Peptide 是PKC 假底物抑制剂/区域。Protein Kinase C (19-35) Peptide 阻断PKC 激酶结构域的底物结合位点,使PKC 的细胞质形式失活。 | |||
T8764 |
PKC-iota inhibitor 1
|
PKC | Chromatin/Epigenetic; Cytoskeletal Signaling |
PKC-iota inhibitor 1 是一种蛋白激酶 C-iota(PKC-ι ℩)的抑制剂,IC50值为 0.34 μM。 | |||
T80071 |
PKCζ/ι pseudosubstrate inhibitor
|
||
PKCζ/ι偽基質抑制劑對PKC酶家族表現廣譜抑制作用,並可能促成記憶功能障礙。 |
Cat. No. | Product Name | Species | Expression System |
---|---|---|---|
TMPY-04455 |
PKC iota Protein, Human, Recombinant (GST)
PKCI,nPKC-iota,protein kinase... |
Human | Baculovirus Insect Cells |
Protein kinase C iota type, also known as Atypical protein kinase C-lambda/iota, aPKC-lambda/iota and PRKCI, is a cytoplasm, membrane and nucleus protein which belongs to the protein kinase superfamily, AGC Ser/Thr protein kinase family and PKC subfamily. PRKCI contains one AGC-kinase C-terminal domain, one OPR domain, one phorbol-ester/DAG-type zinc finger and one protein kinase domain. PRKCI is predominantly expressed in lung and brain, but also expressed at lower levels in many tissues includ... | |||
TMPK-01450 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi), Biotinylated
KRAS1,MHC,K-RAS4B,KRAS,CFC2,K-RAS... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01456 |
HLA-C*03:04&B2M&KRAS G12D (GADGVGKSAL) Tetramer Protein, Human, MHC (His & Avi)
KRAS2,NS,MHC,C-K-RAS,KRAS1,K-RAS2A,K-RAS2B... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. | |||
TMPK-01451 |
HLA-C 03:04&B2M&KRAS G12D (GADGVGKSAL) Monomer Protein, Human, MHC (His & Avi)
NS3,K-RAS4A,K-Ras 2,NS,KRAS1,RASK2,MHC,KI-RAS,KRAS,... |
Human | HEK293 Cells |
Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail. |